The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- National Institutes of Health (NIH) - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of National Institutes of Health (NIH) human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of National Institutes of Health (NIH) with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the National Institutes of Health (NIH)’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate National Institutes of Health (NIH)’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of National Institutes of Health (NIH) in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the National Institutes of Health (NIH)’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with National Institutes of Health (NIH).
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of National Institutes of Health (NIH) and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
National Institutes of Health (NIH) Snapshot 5
National Institutes of Health (NIH) Overview 5
Key Information 5
Key Facts 5
National Institutes of Health (NIH) - Research and Development Overview 6
Key Therapeutic Areas 6
National Institutes of Health (NIH) - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
National Institutes of Health (NIH) - Pipeline Products Glance 11
National Institutes of Health (NIH) Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
National Institutes of Health (NIH)-Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
National Institutes of Health (NIH) - Drug Profiles 14
Florbetapir F 18 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Inositol 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Hepatitis C Virus Clone, Strain HC-TN program 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
HGC-1 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
IGFBP-3 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Isac 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
PB-39B 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
National Institutes of Health (NIH) - Pipeline Analysis 21
National Institutes of Health (NIH) - Pipeline Products by Therapeutic Class 21
National Institutes of Health (NIH) Pipeline Products By Target 23
National Institutes of Health (NIH) - Pipeline Products by Route of Administration 24
National Institutes of Health (NIH) - Pipeline Products by Molecule Type 25
National Institutes of Health (NIH) - Dormant Projects 26
National Institutes of Health (NIH) - Locations And Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Financial Deals Landscape 29
Financial Deals Landscape 29
National Institutes of Health (NIH), Deals Volume Summary, 2004 to YTD 2010 29
National Institutes of Health (NIH), Deals Summary By Region, 2004 to YTD 2010 30
National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010 31
National Institutes of Health (NIH) Detailed Deal Summary 34
Enzo Biochem Enters Into Co-Development Agreement With National Institutes of Health 34
Inovio Biomedical Enters Into Research Agreement With Vaccine Research Center 35
Amsterdam Molecular Therapeutics Enters Into Co-Development Agreement With National Institutes of Health 36
Minster Pharmaceuticals Enters Into Research Agreement With National Institutes Of Health 37
Chaperone Technologies Enters Into Co-Development Agreement With National Institutes Of Health 38
MedImmune Enters Into Co-Development Agreement With National Institutes of Health 39
Crucell Extends Research Agreement With NIH 40
GenVec Enters Into Agreement With Vaccine Research Center 41
Athersys Enters Into Co-Development Agreement With The National Institutes Of Health 42
Licensing Agreements 43
Sequella Amends Licensing Agreement With NIH 43
Repros Amends Licensing Agreement With National Institutes 44
Can-Fite BioPharma Enters Into A Licensing Agreement With Leiden University And NIH 45
Theranostics Health Enters Into Licensing Agreement With National Institutes Of Health 47
NIH Extends Licensing Agreement with Genomatix Software 48
NeoPharm Enters Into Licensing Agreement With National Institute Of Health 49
GenVec Enters Into Licensing Agreement With Vaccine Research Center 51
Tigris Pharmaceuticals Enters Into Licensing Agreement With National Institutes Of Health 52
Axxam Enters Into Licensing Agreement With National Institutes of Health 53
Panacea Biotec Enters Into Licensing Agreement With National Institute of Health 54
Crucell Enters Into Licensing Agreement With NIH 55
GenVec Enters Into Licensing Agreement With National Institutes of Health 56
Targeted Genetics Enters Into Licensing Agreement With NIH 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 59
Contact Us 59
Disclaimer 59List of Tables
National Institutes of Health (NIH) - Pipeline by Therapy Area and Indication, 2010 8
National Institutes of Health (NIH) - Pipeline by Stage of Development, 2010 9
National Institutes of Health (NIH) - Monotherapy Products in Pipeline, 2010 10
National Institutes of Health (NIH) - Phase II, 2010 11
National Institutes of Health (NIH) - Pipeline By Therapeutic Class, 2010 22
National Institutes of Health (NIH) - Pipeline By Target, 2010 23
National Institutes of Health (NIH) - Pipeline By Route of Administration, 2010 24
National Institutes of Health (NIH) - Pipeline By Molecule Type, 2010 25
National Institutes of Health (NIH) - Dormant Developmental Projects, 2010 26
National Institutes of Health (NIH), Other Locations 27
National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010 29
National Institutes of Health (NIH), Deals Summary by Region, 2004 to YTD 2010 30
National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010 31
National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010 33

List of Figures
National Institutes of Health (NIH) - Pipeline by Therapy Area and Indication, 2010 7
National Institutes of Health (NIH) - Pipeline by Stage of Development, 2010 9
National Institutes of Health (NIH) - Monotherapy Products in Pipeline, 2010 10
National Institutes of Health (NIH) - Pipeline By Therapeutic Class, 2010 21
National Institutes of Health (NIH) - Pipeline By Target, 2010 23
National Institutes of Health (NIH) - Pipeline By Route of Administration, 2010 24
National Institutes of Health (NIH) - Pipeline By Molecule Type, 2010 25

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.